Cardiometabolic Disease
Park Inn by Radisson Danube Bratislava
Objectives of the CRT meeting in Cardiometabolic Disease:
- Understanding the scope of cardiometabolic disease along life cycle, common pathophysiologic basis, classical and emerging risk factors, global and precision risk prediction (biomarkers, imaging, omics and AI)
- Approaching determinants of cardiometabolic health - role of genetics, epigenetics, environment and human behavior
- Focusing intervention on cardiometabolic disease prevention, in line with the EU CV plan- lifestyle changes implementation, novel therapies and integrated care
- Identification of gaps in cardiometabolic landscape
- Proposals for implementation projects in Europe
- Imperative for prevention: Foreseeing the future of cardiometabolic disease management and the role of AI support
|
12:00 - 13:30 |
Arrivals and Buffet Lunch |
|
|
Day 1 | 18 March 2026 | 13:30 – 18:40 CET | MEETING ROOM: BRATISLAVA |
||
|
13:30-13:35 |
Welcome from the CRT Chairpersons |
Cecilia Linde Bettina Kraus (BI) |
|
13:35 -15:15 SESSION 1.1 – The Evolving picture of cardiometabolic disease Moderated by: Ana Abreu and Prodromos Anthopoulos (Cytokinetics) |
||
|
13:35-13:45
|
EU CV health plan: cardiometabolic disease in perspective |
Thomas F Lüscher
|
|
13:45-13:55
|
Patterns, causes and risk factors (classical and emergent) of cardiometabolic disease |
Francesco Cosentino |
|
13:55-14:05
|
Shared pathophysiology for diverse clinical presentations: inflammation, adipose tissue biology, insulin resistance |
Maria Marketou |
|
14:05-14:15
|
Global and precision risk prediction along life cycle: biomarkers, imaging, omics and machine learning
|
Emanuelle Di Angelantonio
|
|
14:15-14:45 |
PANEL DISCUSSION |
|
|
14:45-15:15 |
Coffee break |
|
|
15:15 -18:40 SESSION 1.2 – Determinants of cardiometabolic health Moderated by: John Deanfield and Monika Gratzke (Daiichi-Sankyo) |
||
|
15:15-15:25
|
The role of genetics and epigenetics
|
|
|
15:25-15:35
|
The role of environment
|
Paul Dendale |
|
15:35-15:45
|
The role of human behaviour
|
Lis Neubeck
|
|
15:45- 15:55
|
How to deal with the Determinants of Cardiometabolic Health |
Massimo Piepoli
|
|
15:55-16:30 |
PANEL DISCUSSION |
|
|
16:30-16:35 |
Active break |
|
|
16:35-17:35 |
BREAKOUT SESSIONS Identify and deal with the Gaps in cardiometabolic disease |
|
|
Group 1 Room: Bratislava Prevention and treatment gap: Lack of implementation
|
Lead: Matthias Wilhelm Rapporteur: Michael Madigan (ESC Patient Forum) |
|
|
Group 2: Room: Pressburg Research gap: What is unknown about new drugs’ effect
|
Lead : Maddalena Lettino Rapporteur: Ahmad Alhussein (BI) |
|
|
Group 3: Room: Istropolis Health equity gap : Challenges for access to prevention and treatment in different population sectors
|
Lead: Paul Dendale Rapporteur: Massimo Piepoli |
|
|
17:35-17:45 |
Report from breakout session 1 –10 mins |
Rapporteur : Michael Madigan |
|
17:45-17:55 |
Report from breakout session 2 – 10 mins |
Rapporteur : Ahmad Alhussein (BI) |
|
17:55-18:05 |
Report from breakout session 3 – 10 mins |
Rapporteur : Massimo Piepoli |
|
18:05-18:30 |
PANEL DISCUSSION |
|
|
18:30-18:40 |
Wrap-up and summary Day 1 – Outlook to Day 2 |
Ana Abreu, Katja Rohwedder (Bayer) |
|
END OF DAY 1 |
||
|
19:30 |
APERITIF +DINNER |
|
|
|
||
|
Day 2 | 19 March 2026 | 08:30 – 12:30 CET | MEETING ROOM: BRATISLAVA |
||
|
08:30-08:40 |
Summary of day 1 |
Ana Abreu John Deanfield |
|
|
8:40 - 10:40 - SESSION 2.1: Intervention focus on cardiometabolic disease Moderated by : Dr Monika Gratzke (Daiichi-Sankyo) and Dr Katja Rohwedder (Bayer) |
|
||
|
08:40-08:50 |
Lifestyle changes for global prevention and implementation strategies at individual and population-level |
Ana Abreu | |
|
08:50-09:00
|
Novel therapies and integrated care models in clinical management of diabetes, hypertension, dyslipidemia and obesity |
John Deanfield |
|
|
09:00-09:20 |
PANEL DISCUSSION |
|
|
|
09:20-10:10
|
BREAKOUT SESSIONS INNOVATIVE RESEARCH PROJECTS DESIGN IN CARDIOMETABOLIC LANDSCAPE |
|
|
|
Topic proposal: Obesity and/or diabetes |
Lead: Cecilia Linde Rapporteur: Klaus Kuhlbusch (Roche Pharma) |
|
|
|
Group 5: Room: Pressburg Chronic Kidney Disease and/or Hypertension
|
Lead: Eva Gerdts Rapporteur: Maria Ripa (Novonordisk) |
|
|
|
Group 6: Room: Istropolis The role of the gut and liver on cardiometabolic risk profile
|
Lead: Tomasz Guzik Rapporteur: Daniela Fliegner(Pfizer)
|
|
|
|
10:10-10:20 |
Report&Comments from breakout session 4 – 5+5 mins |
Rapporteur: Klaus Kuhlbusch (Roche Pharma) |
|
|
10:20-10:30 |
Report&Comments from breakout session 5 – 5+5 mins |
Rapporteur: Maria Ripa (Novonordisk) |
|
|
10:30-10:40 |
Report&Comments from breakout session 6 – 5+5 mins |
Rapporteur: Daniela Fliegner (Pfizer) |
|
|
10:40-10:45 |
Active break |
|
|
|
10:45-11:10 |
Coffee break |
|
|
|
11:10 - 12:30 - SESSION 2.2: What will the future bring: a bird´s eye view Moderated by: Prodromos Anthopoulos (Cytokinetics) and John Deanfield and Ana Abreu |
|
||
|
11:10-11:20
|
Prevention rather than cure in cardiometabolic disease: a call for action |
Constantinos Davos |
|
|
11:20-11:30 |
Patient’s perspective |
Konstantina Boumaki |
|
|
11:30-11:40
|
AI transforming the future of cardiometabolic disease |
Rubens Casado Arroy (via zoom) |
|
|
11:30-12:20 |
PANEL DISCUSSION and NEXT STEPS |
|
|
|
12:20-12:30 |
Wrap-up & conclusion |
Cecilia Linde Bettina Kraus (BI) |
|
|
END OF DAY 2 |
|
||
|
12:30 |
Buffet lunch and departures |
|
|
Academic Chairpersons
Industry Chairpersons
Doctor Prodromos Anthopoulos
Cytokinetics
Doctor Monika Gratzke
Daiichi-Sankyo
Doctor Katja Rohwedder
Bayer
Doctor Bettina Kraus
Boehringer Ingelheim